A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a
phase 1 dose escalation and expansion section to identify maximum tolerated
dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 23~116 subjects, and a
phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple
myeloma.